Payment overview · 2025
General Payments
$386.72
22 reported records · 10 companies
Healthcare provider profile · identity verified
Stacy Lee Riedt, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MONTPELIER, VA · NPI 1982926317
Verified facts
What the public records show
CMS Open Payments records show Stacy Lee Riedt, FNP-BC received $386.72 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $173.75 | 44.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.79 | 11.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.86 | 8.8% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $29.98 | 7.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.12 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.12 | 5.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.33 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.35 | 4.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.63 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.79 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $386.72 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $69.28 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.06 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.79 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.79 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $29.98 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 122 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 754 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 743 | 179 |
| Lisinopril | Lisinopril | 495 | 133 |
| Alprazolam | Alprazolam | 472 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 107 |
| Omeprazole | Omeprazole | 433 | 112 |
| Gabapentin | Gabapentin | 340 | 84 |
| Metformin Hcl | Metformin Hcl | 319 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 318 | 76 |
| Glipizide | Glipizide | 295 | 73 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 278 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 265 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 260 | 72 |
| Prednisone | Prednisone | 254 | 176 |
| Fluoxetine Hcl | Fluoxetine Hcl | 247 | 60 |
| Simvastatin | Simvastatin | 223 | 53 |
| Cephalexin | Cephalexin | 219 | 161 |
| Diazepam | Diazepam | 213 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 53 |
| Losartan Potassium | Losartan Potassium | 195 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 47 |
| Lorazepam | Lorazepam | 187 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 48 |
| Sertraline Hcl | Sertraline Hcl | 186 | 39 |
| Azithromycin | Azithromycin | 185 | 142 |
| Allopurinol | Allopurinol | 174 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 172 | 40 |
| Meloxicam | Meloxicam | 172 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 151 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 147 | 18 |
| Montelukast Sodium | Montelukast Sodium | 145 | 24 |
| Bumetanide | Bumetanide | 133 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 23 |
| Eliquis | Apixaban | 122 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 115 | 91 |
| Trazodone Hcl | Trazodone Hcl | 112 | 26 |
| Carvedilol | Carvedilol | 111 | 24 |
| Clonazepam | Clonazepam | 106 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 23 |
| Potassium Chloride | Potassium Chloride | 104 | 27 |
| Famotidine | Famotidine | 103 | 27 |
| Pregabalin | Pregabalin | 103 | 16 |
| Tramadol Hcl | Tramadol Hcl | 101 | 24 |
| Farxiga | Dapagliflozin Propanediol | 99 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 93 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 21 |
| Furosemide | Furosemide | 90 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 21 |
| Atenolol | Atenolol | 88 | 20 |
| Lovastatin | Lovastatin | 88 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 17 |
| Glimepiride | Glimepiride | 77 | 18 |
| Ezetimibe | Ezetimibe | 74 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 59 |
| Ibuprofen | Ibuprofen | 69 | 15 |
| Nystatin | Nystatin | 69 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 22 |
| Bupropion Xl | Bupropion Hcl | 62 | 16 |
| Fluconazole | Fluconazole | 62 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | suppressed |
| Amoxicillin | Amoxicillin | 58 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 43 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 15 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 18 |
| Ozempic | Semaglutide | 47 | suppressed |
| Topiramate | Topiramate | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 12 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 11 |
| Colchicine | Colchicine | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 12 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lamotrigine Odt | Lamotrigine | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nylia | Norethindrone-Ethin. Estradiol | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Rinvoq | Upadacitinib | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Tlando | Testosterone Undecanoate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $386.72 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dyanavel XR, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, MOUNJARO, NURTEC ODT, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error